Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
The latest tech and tools for cell and gene therapy
Learn about innovations that support scientists in...
Limit your risk, avoid waste and ensure compliance to government legislation
This paper provides an overview of the importance...
How to accelerate biologics discovery and save up to 60% in costs
Boosting sustainable production: success story of...
